Adrienne Dorrance

Dr. Adrienne Dorrance


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2015 in Leukemia
Verified
Journal Article
Open access
PDF file
ADAdrienne Dorrance
Adrienne Dorrance
PNP Neviani
P Neviani
GFG J Ferenchak
G J Ferenchak
XHX Huang
X Huang
DND Nicolet
D Nicolet
GMG Marcucci
G Marcucci
Current treatments for acute myeloid leukemia (AML) are designed to target rapidly dividing blast populations with limited success in eradicating the functionally distinct leukemia stem cell (LSC) population, which is postulated to be responsible for disease resistance and relapse. We have previously reported high miR-126 expression levels to be associated with a LSC-gene expression profile. Therefore, we hypothesized that miR-126 contributes to ‘stemness’ and is a viable target for eliminating the LSC in AML. Here we first validate the clinical relevance of miR-126 expression in AML by showing that higher expression of this microRNA (miR) is associated with worse outcome in a large cohort of older (⩾60 years) cytogenetically normal AML patients treated with conventional chemotherapy. We then show that miR-126 overexpression characterizes AML LSC-enriched cell subpopulations and contributes to LSC long-term maintenance and self-renewal. Finally, we demonstrate the feasibility of therapeutic targeting of miR-126 in LSCs with novel targeting nanoparticles containing antagomiR-126 resulting in in vivo reduction of LSCs likely by depletion of the quiescent cell subpopulation. Our findings suggest that by targeting a single miR, that is, miR-126, it is possible to interfere with LSC activity, thereby opening potentially novel therapeutic approaches to treat AML patients.

11 March 2019 in Leukemia
Verified
Journal Article
Closed access
PDF file
MBMarius Bill
Marius Bill
DPDimitrios Papaioannou
Dimitrios Papaioannou
MKMalith Karunasiri
Malith Karunasiri
JKJessica Kohlschmidt
Jessica Kohlschmidt
FPFelice Pepe
Felice Pepe
ADAdrienne Dorrance
Adrienne Dorrance

22 May 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
DPDimitrios Papaioannou
Dimitrios Papaioannou
CSChangxian Shen
Changxian Shen
DNDeedra Nicolet
Deedra Nicolet
BMBetina McNeil
Betina McNeil
MBMarius Bill
Marius Bill
ADAdrienne Dorrance
Adrienne Dorrance
Significance: In this work we report on the previously uncharacterized clinical and biological role for EGFL7 in acute myeloid leukemia (AML). Patients with increased EGFL7 mRNA expression had lower complete remission rates and shorter overall and event-free survival, demonstrating the clinical relevance of EGFL7 expression in cytogenetically normal AML. Our results show that AML blasts are able to synthesize and secrete EGFL7 protein, promoting autocrine blast cell growth. Inhibition of EGFL7 results in decreased proliferation and induces apoptosis of AML cells. Taken together, our data provide the rationale for targeting EGFL7 using blocking antibodies as a therapy for patients with AML.

1 February 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MBMarius Bill
Marius Bill
APAparna Pathmanathan
Aparna Pathmanathan
MKMalith Karunasiri
Malith Karunasiri
CSChangxian Shen
Changxian Shen
MBMatthew H. Burke
Matthew H. Burke
ADAdrienne Dorrance
Adrienne Dorrance
Purpose: Epidermal growth factor-like domain 7 (EGFL7) is a secreted protein and recently has been shown to play an important role in acute myeloid leukemia (AML); however, the underlying mechanism by which EGFL7 promotes leukemogenesis is largely unknown. Experimental Design: Using an antibody interaction-array we measured the ability of EGFL7 to bind directly ~400 proteins expressed by primary AML blasts. Primary patient samples were stimulated in vitro with recombinant EGFL7 (rEGFL7) or anti-EGFL7 blocking antibody to assess alterations in downstream signaling and the ability to effect blast differentiation and survival. We treated three independent AML models with anti-EGFL7 or IgG1 control to determine whether anti-EGFL7 could prolong survival in vivo. Results: We found EGFL7 significantly binds several signaling proteins important for normal and malignant hematopoiesis including NOTCH. Stimulation of AML blasts with rEGFL7 reduced NOTCH intracellular domain and NOTCH target gene expression while treatment with an anti-EGFL7 blocking antibody resulted in reactivation of NOTCH signaling, increased differentiation, and apoptosis. Competitive ligand binding assays showed rEGFL7 inhibits DELTA-like (DLL) 4-mediated NOTCH activation while anti-EGFL7 combined with DLL4 significantly increased NOTCH activation and induced apoptosis. Using three different AML mouse models, we demonstrated that in vivo treatment with anti-EGFL7 alone results in increased survival. Conclusions: Our data demonstrates that EGFL7 contributes to NOTCH silencing in AML by antagonizing canonical NOTCH ligand binding. Reactivation of NOTCH signaling in vivo using anti-EGFL7 results in prolonged survival of leukemic mice, supporting the use of EGFL7 as a novel therapeutic target in AML.

Verified
Journal Article
Open access
PDF file
ARAlexander David Rudich
Alexander David Rudich
RGRamiro Garzon
Ramiro Garzon
ADAdrienne Dorrance
Adrienne Dorrance
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm initiated by the presence of the fusion gene BCR::ABL1. The development of tyrosine kinase inhibitors (TKIs) highly specific to p210BCR-ABL1, the constitutively active tyrosine kinase encoded by BCR::ABL1, has greatly improved the prognosis for CML patients. Now, the survival rate of CML nearly parallels that of age matched controls. However, therapy resistance remains a persistent problem in the pursuit of a cure. TKI resistance can be attributed to both BCR::ABL1 dependent and independent mechanisms. Recently, the role of non-coding RNAs (ncRNAs) has been increasingly explored due to their frequent dysregulation in a variety of malignancies. Specifically, microRNAs (miRNAs), circular RNAs (circRNAs), and long non-coding RNAs (lncRNAs) have been shown to contribute to the development and progression of therapy resistance in CML. Since each ncRNA exhibits multiple functions and is capable of controlling gene expression, they exert their effect on CML resistance through a diverse set of mechanisms and pathways. In most cases ncRNAs with tumor suppressing functions are silenced in CML, while those with oncogenic properties are overexpressed. Here, we discuss the relevance of many aberrantly expressed ncRNAs and their effect on therapy resistance in CML.

13 May 2021 in Haematologica
Verified
Journal Article
Open access
PDF file
MBMarius Bill
Marius Bill
CGChinmayee Goda
Chinmayee Goda
FPFelice Pepe
Felice Pepe
HOHatice Gulcin Ozer
Hatice Gulcin Ozer
BMBetina McNeil
Betina McNeil
ADAdrienne Dorrance
Adrienne Dorrance